MenQuadfi

Meningococcal group A, C, W & Y conjugate vaccine

Active immunisation of individuals ≥12 mth against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W & Y.

IM Primary vaccination Individual ≥12 mth 0.5 mL single dose. Booster vaccination Individual who previously received meningococcal vaccine containing the same serogroups 0.5 mL single dose.

Hypersensitivity to the vaccine or after previous administration of vaccine or vaccine containing the same components.

Not to be administered SC, intravascularly or intradermally. Not to be used as protection against any other Neisseria meningitidis groups. Not a substitute for routine tetanus immunisation. Postpone vaccination in individuals suffering from acute severe febrile illness. Syncope & other anxiety-related reactions following or before any vaccination. Increased risk of invasive disease caused by Neisseria meningitidis groups A, C, W & Y in persons w/ familial complement deficiencies (eg, C5 or C3) & persons receiving treatments inhibiting terminal complement activation (eg, eculizumab). Individuals w/ thrombocytopenia or any coagulation disorder that would contraindicate IM inj; at high risk for MenA infection who received MenC-CRM vaccine in their 1st yr of life. Immunocompromised patients. Patients receiving immunosuppressive treatment or w/ immunodeficiency. Review medical history especially w/ regard to previous vaccination & possible occurrence of undesirable effects & perform clinical exam preceding vaccination. Appropriate medical treatment & supervision should be readily available in case of anaphylactic event following vaccination. May temporarily affect ability to drive or use machines. Pregnancy & lactation. Paed <12 mth.

Inj site tenderness/pain, swelling & erythema. Fever. Subjects ≥2 yr: Headache; myalgia; malaise. Subjects 12-23 mth: Loss of appetite; irritability; drowsiness; abnormal crying. Vomiting, diarrhoea.

Concomitant use w/ PCV-13 vaccines. May not elicit adequate immune response w/ immunosuppressive treatment.

Vaccines, Antisera & Immunologicals

J07AH08 - meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated ; Belongs to the class of meningococcal bacterial vaccines.

S